BACKGROUND: CD34 flow cytometry is the gold standard for stem cell enumeration in peripheral blood at the mobilization stage and in the final apheresis product. The new stem cell mode of the Sysmex XN Series analyzer enumerates an immature cell population in the white progenitor and pathological cell (WPC) channel, based on the cell size, internal cellular complexity, and fluorescence intensity.
RESULTS:
In this multicenter study we demonstrate that the XN stem cell enumeration method correlates well with viable CD341 cells determined by flow cytometry during the stem cell mobilization phase to determine apheresis start time, during apheresis for real-time monitoring and adjustment, and for quality control of the final stem cell harvest.
CONCLUSION: Our data show that there is an improvement in the correlation of XN stem cells and CD341 cells in the peripheral blood during stem cell mobilization as well as in stem cell harvests compared to SE or XE Series analyzers. The XN stem cell enumeration method has a number of advantages compared to CD34 flow cytometry: it is fast, simple, reproducible, and less expensive. CE marking for the European market has been obtained, making the stem cell count on the XN analyzer a reportable clinical variable.
H ematopoietic stem cell transplantation is a common treatment modality implicated in high-risk malignant hematologic diseases, immunologic or metabolic disorders, and solid tumors. 1 Currently, almost all autologous and allogeneic stem cell donors will undergo stem cell mobilization and only in case of failure will have marrow harvested. 2 Hematopoietic stem cells obtained by apheresis (HPC(A)) have multiple advantages over marrow as the collection of HPC(A) does not require general anesthesia and is less invasive, and transplantation of HPC(A) leads to faster engraftment of neutrophils and platelets. 3 HPCs can be mobilized from the marrow into the peripheral blood by administering human hematopoietic growth factors like granulocyte-colony-stimulating factor (G-CSF) with or without chemotherapy. 4 Currently, the CD34 antigen is the best surrogate marker for the enumeration of hematopoietic progenitor and stem cells. 5 The number of infused viable CD341 cells strongly correlates with the time to hematologic recovery of the patient. 6 It is essential to predict stem cell yields to guide important clinical decisions such as the start of stem cell apheresis, the blood volume to be processed, and the number of apheresis procedures to be performed. The International Society of Hematotherapy and Graft Engineering (ISHAGE) lists a single-platform (SP) flow cytometry method using beads, monoclonal antibodies against the CD34 and CD45 antigen, and a viability dye as the "gold standard" for enumeration of viable CD341 cells. 5, 7, 8 The drawback of this method is that flow cytometric analysis of CD341 cells requires considerable technical skills and is time-consuming (at least 45 min), expensive, and often, due to these factors, not available 24 hours per day. Sysmex has developed technology for the XN Series hematology analyzers that allows the identification of hematopoietic stem cells based on fluorescence intensity, which in turn depends on the lipid composition of the cell membrane, nucleic acid content, cell size, and complexity of the intracellular structures. This analysis is faster (4 min) and cheaper and requires less technical expertise. Moreover, it has 24-hour availability in a routine hematology laboratory setting as it can be performed as part of routine complete blood count analysis. Peerschke and colleagues 9 published data from a single-center study on this latest XN technology. Here we confirm their results with a larger data set from three hospitals. In addition, we evaluated if the XN stem cell enumeration can be a valuable tool for stem cell collection management by determining the coefficient of variation (CV) and medical decision point of this method and by analyzing samples during stem cell harvest.
MATERIALS AND METHODS

Study design
This multicenter study was performed at the Erasmus Medical Center Rotterdam, the Academic Medical Center Amsterdam, and the Maastricht University Medical Centre in the Netherlands. Every study site obtained approval from their medical ethical committee. Patient and donor characteristics are presented in Table 1 . A complete blood count was determined daily in transplant recipients during stem cell mobilization phase and in healthy donors on the day of stem cell apheresis.
Stem cell mobilization and apheresis
Stem cells were mobilized in autologous patients by chemotherapy (kind and dose depending on the disease) and daily injections with 5 to 10 mg/kg/day human recombinant G-CSF subcutaneously (Amgen, Ireland; or Sandoz, Austria) and in allogeneic donors by daily injections with 10 mg/kg/day G-CSF for 4 to 5 days. Apheresis was started once the number of stem cells in the peripheral blood reached at least 20 3 10 6 /L and was performed with a blood cell separator (COBE Spectra or Spectra Optia, Terumo BCT). On average one apheresis cycle was needed to obtain sufficient numbers of HPCs, but up to three cycles were needed for some patients. Apheresis was stopped once the number of stem cells in the apheresis product reached at least 2 310 6 to 5 310 6 /kg.
Sample collection
A total of 18 healthy donors and 84 adult patients were enrolled in this study. In total 214 samples were collected and categorized as M samples (peripheral blood collected in EDTA tubes during the mobilization phase, n 5 147), C samples (collected during collection of stem cells-apheresis [COBE Spectra], n 5 22), and P samples (collected from the apheresis product, n 5 45). All samples were analyzed by CD34 flow cytometry and XN Series analyzers within 3 hours. XN-stem cell count was determined in all M, C, and P samples to compare to CD341 cell count determined by flow cytometry.
CD34 flow cytometry
In two of three centers CD34 flow cytometry was performed by the single-platform method according to the guidelines of the ISHAGE. 5, 7, 8, 10 In the other center the dual-platform method (CD341 cells calculated by the number of nucleated cells determined on a hematology analyzer and the percentage of CD341 cells determined by the flow cytometer) was used. The methodologies in short: for the single-platform method EDTA blood was labeled with fluorescent antibodies against CD34 and CD45 and stained with 7-AAD or DAPI to determine cell viability and red blood cells (RBCs) were lysed with ammonium chloride buffer; for the dual-platform method EDTA blood was labeled with fluorescent antibodies against CD14, CD66, CD34, and CD45 and RBCs were lysed with FACS lysing solution (Becton Dickinson). For both methods measurements were subsequently performed on a flow cytometer (BD FACSCanto II, Becton Dickinson). A comparison between the three study sites for flow cytometric CD34 cell count performance was done before the start of the study. Three stem cell samples (with low, medium, and high CD341 cell counts) were divided into three aliquots and transported to all three sites for near-simultaneous flow cytometric analysis within 2.5 hours of sample collection.
Stem cell measurements on XN Series analyzers
XN stem cell counts were measured fully automated on a hematology analyzer (XN-1000, Sysmex) using the stem cell mode on the white progenitor and pathological cell (WPC) channel (HPC mode). Measurements were performed according to the manufacturer's instructions. Measurement involves hemolysis of RBCs followed by partial permeabilization of white blood cells, fluorescent staining of RNA or DNA, and subsequent analysis by flow cytometry. Detection of side-scattered light, forwardscattered light, and side fluorescent scatter is used to determine cell granularity, cell size, and fluorescence intensity. Fluorescence intensity depends on the degree of permeabilization of the cell, which differs between cell populations of different lineages and maturity stages due to various lipid composition of cell membranes and on the content of nucleic acids in the cell. The XN stem cell fraction is visible as a cell population in the WPC scattergram ( Fig. 1) . Membranes of nonviable and apoptotic cells react differently with the XN reagents than viable cells. Therefore, after XN staining, nonviable and apoptotic stem cells do not appear in the stem cell gate. The XN-1000 requires 200 mL of sample for analysis, and the absolute XN stem cell count is reported within 4 minutes as a mean of four consecutive measurements.
Repeatability and time stability
Intraanalyzer repeatability was determined by five sequential XN stem cell measurements of the same sample (M sample, n 5 38; P sample, n 5 3). A trend line was made by power regression. The stability of M samples stored at room temperature (n 5 31) or at 48C (n 5 22) was determined by XN stem cell measurements after 0, 1, 8, and 24 hours. Time stability was assessed by using two-way analysis of variance. The stability of P samples stored at room temperature (n 5 5) was determined after 0, 2, 3, 4, 5, and 8 hours.
Statistical analysis
Correlation and regression were assessed by using Spearman's correlation test and Passing-Bablok regression analysis using MedCalc.
RESULTS
Patients and materials
Between October 2012 and February 2013 a total of 18 healthy donors and 84 patients (both pediatric and adult) were enrolled in this study. A total of 147 mobilized blood samples (M samples), 22 samples taken during stem cell collection (C samples), and 45 samples taken from the stem cell final product that was harvested by apheresis (P samples) were analyzed.
Prestudy evaluation of flow cytometric performance
Three stem cell samples with high, medium, and low CD34 count were analyzed by each site (data not shown). All results fall within the 10% range from the mean. In addition, the performance of each laboratory in the external quality control (QC) program UK NEQAS CD34 Stem Cell Enumeration (UK NEQAS, Sheffield, UK) was confirmed to be satisfactory.
Repeatability of XN HPC enumeration
Repeatability of XN stem cell enumeration was evaluated by measuring 38 different M samples (range, 1 3 10 6 -380 3 10 6 cells/L) five times consecutively and the mean and CV was calculated ( Fig. 2A) . The trendline has a correlation coefficient of R 2 5 0.5781. A variation up to 20% was deemed acceptable as is with other in vitro analyses. Only for low values CVs are higher, but this is also known for CD34 counts determined by flow cytometry. 11 At the medical decision point (see below)
the CV is 15.5%. 
Correlation between XN stem cell and CD34 counts
Overall correlation between CD341 cells determined by flow cytometry and XN stem cells determined by the Sysmex XN analyzer for all samples, peripheral blood (M samples), samples during collection (C samples), and product (P samples) was determined (Fig. 3) . All samples showed a very good correlation between the number of XN stem cells and the number of CD34 cells in all samples (M 1 P 1 C) as shown by the correlation coefficient of r 5 0.973 (Fig. 3A) . In addition, correlation in the subgroup of peripheral blood samples (M samples) is very strong (r 5 0.917; Fig. 3B ). The medical decision point for starting apheresis of 20 3 10 6 CD34/L correlates with 19.5 3 10 6 HPCs/L. Thus, when using the XN stem cell measurement, the medical decision point for starting an apheresis procedure will be 19.5 3 10 6 HPCs/L. At the medical decision point the CV is 15.5%, which is above the limit of quantitation. Therefore, with an XN stem cell measurement of more than 19.5 3 10 6 HPCs/L, a reliable decision can be made to start apheresis. The XN stem cell concentration in the 3-L apheresis products (C samples) and final stem cell harvest products (P samples) also correlates very well with the CD34 concentration in these products (r 5 0.975 and r 5 0.936, respectively; Figs. 3C and 3D, respectively), although the 95% confidence interval (CI) lines show a wider range compared to all samples (Fig. 3A) and M samples (Fig. 3B) . To determine if the preharvest XN stem cell level count can be used as indicator for a successful harvest of more than 2 3 10 6 CD34/kg, we examined the correlations between the preharvest CD34 or XN stem cell count and the number of harvested CD34 cells. The correlation between preharvest CD34 count and the CD34 harvest is strong: r 5 0.901 (Fig. 4A) . The correlation between preharvest XN stem cell count and the CD34 harvest is good-r 5 0.785 (Fig. 4B )-and the highest published thus far.
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DISCUSSION
CD34 flow cytometry is a standard method of stem cell enumeration in peripheral blood at the mobilization stage and in the final apheresis product. It requires well-trained and experienced flow cytometer operators and is a technique that can be technically challenging. 5, 7, 8, 10, 20 The new XN stem cell mode of the Sysmex XN Series analyzer enumerates an immature cell population in the WPC channel, based on the cell size, internal cellular complexity, and fluorescence intensity. With immunomagnetic selection of CD341 cells, it was recently demonstrated that the XN stem cell population is comparable to CD341 cells. 21 In this multicenter study XN stem cell and flow cytometric CD34 enumeration were compared in samples collected during stem cell mobilization and stem cell collection and from the final stem cell harvest from both pediatric and adult patients and healthy donors. XN stem cell measurements show acceptable repeatability and stability performance in peripheral blood and stem cell harvests. We found very good correlations between peripheral blood XN stem cells and CD34 counts determined by flow cytometry. Our data show that there is an improvement in the correlation of XN stem cells and CD341 cells in the peripheral blood during stem cell mobilization as well as in stem cell harvests as compared to SE or XE Series analyzers. 9, [12] [13] [14] [15] [16] [17] [18] [19] [22] [23] [24] [25] [26] [27] [28] This has been achieved by adapting reagent composition, cell detection method, and the stem cell identification algorithm in this new version of the Sysmex hematology analyzer, as was also demonstrated in the data of Peerschke and coworkers. 9 In conclusion, in this study we demonstrate that XN stem cell method correlates well with the gold standard of CD34 flow cytometry during stem cell mobilization phase to determine apheresis start time, during apheresis for real-time monitoring and adjustment, and for QC of the final stem cell harvest. Moreover the medical decision point for apheresis is above the limit of quantitation of the XN analyzer. The XN stem cell enumeration method has a number of advantages compared to CD34 flow cytometry: it is fast, simple, and less expensive. These advantages of the XN stem cell enumeration and its good correlation with the number of live CD341 cells determined by flow cytometry make this method suitable for indicating when to start to harvest stem cells during mobilization phase. In addition, the rapid availability of XN stem cell counts allows inprocess adjustment of processed blood volume during stem cell collection, making apheresis procedures as short as possible.
The stem cell count on the XN analyzer has become a reportable clinical variable now the new software version has been installed and CE marking for the European market has been obtained. For the universal application of this method in stem cell transplantation practices, it is important that other sources of stem cells can be measured as well, such as marrow HPCs and cryopreserved cord blood HPCs when a matched unrelated HPC(A) donor is not available. The performance of the XN stem cell module needs to be validated for these stem cell sources and in particular if viable stem cells in thawed cryopreserved products can be determined accurately. 
